Tezspire Injection, Solution
Product Images NDC 55513-123

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tezspire (NDC 55513-123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-apfs-sales (Carton Apfs Sales)

TEZSPIRE (tezepelumab-ekko) Injection 210 mg/1.91 mL (110 mg/mL) pre-filled single-dose syringe label. The label indicates subcutaneous injection, storage refrigerated at 36-46°F (2-8°C), and not to shake, freeze, or expose to heat. Manufactured by AstraZeneca AB and marketed by Amgen Inc. and AstraZeneca AB. NDC 55513-112-01.*

FDA Label Image

Carton (Carton Vial)

Label for TEZSPIRE (tezepelumab-ekko) injection, 210 mg per 1.91 mL (110 mg/mL), for subcutaneous injection. The label indicates a single-dose vial and instructs to discard any unused portion. The product is Rx only and labeled by Amgen Inc and AstraZeneca. NDC 55513-100-01 is visible.*

FDA Label Image

Figure_1 (Figure1 Needle)

An instructional diagram of a prefilled syringe illustrating the components before and after use. Labeled parts include needle guard activation clips, plunger head, plunger, finger flange, viewing window, syringe body, label with expiration date, needle, needle cover, and needle guard.*

FDA Label Image

Figure_2 (Figure 2)

A forest plot showing rate ratios with 95% confidence intervals comparing TEZSPIRE 210 mg/1.9 mL to placebo across different subgroups based on eosinophil count and FeNO levels at baseline. The plot includes data points and confidence intervals indicating the relative effect favoring TEZSPIRE or placebo, with the rate ratio scale presented below the graph.*

FDA Label Image

Figure_3 (Figure 3)

A Kaplan-Meier curve graph depicting time to first asthma exacerbation over 60 weeks for TEZSPIRE 210 mg/1.9 mL versus placebo. The x-axis represents time (weeks), and the y-axis shows probability of event. The graph compares event probabilities between TEZSPIRE treatment and placebo groups.*

FDA Label Image

Figure_4 (Figure 4)

A line graph comparing pre-bronchodilator FEV1 change from baseline over 52 weeks between TEZSPIRE and placebo groups. The graph shows mean values with 95% confidence intervals, with time in weeks on the x-axis and change in FEV1 on the y-axis. TEZSPIRE exhibits a greater increase in FEV1 than placebo throughout the study period.*

FDA Label Image

Number_3_picture (Number3picture)

An instructional illustration showing a hand removing the cap from a syringe. The image features the syringe held by one hand and the cap being pulled off with the other, indicated by an arrow pointing away from the syringe tip.*

FDA Label Image

Number4picture (Number4picture)

An instructional illustration showing a hand holding a syringe with a needle inserted into the fingertip of the other hand, demonstrating a fingerstick blood collection technique. The syringe is depicted with a visible plunger and needle cap, and the finger has a small drop of blood emerging from the puncture site.*

FDA Label Image

Number5picture (Number5picture)

An instructional illustration showing a hand holding a pen-like injector device administering a subcutaneous injection into the forearm of the other hand. The image emphasizes the proper injection technique by depicting the needle insertion angle and hand positioning for the TEZSPIRE 210 mg/1.9 mL injectable product by Amgen Inc.*

FDA Label Image

Number6picture (Number6picture)

An instructional illustration showing a hand holding a TEZSPIRE 210 mg/1.9 mL prefilled syringe. The image demonstrates the removal of a needle cap by pulling it straight upwards, indicated by an arrow above the cap.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.